TEM Latest Headlines

Tempus spotlights AI pre-screening in advanced NSCLC with 60,459-case analysis ahead of ESMO 2026

Market Chameleon (Tue, 20-Oct 7:14 AM)

Tempus sets Nov. 2 Q3 2026 earnings call with CEO Eric Lefkofsky and CFO Jim Rogers

Market Chameleon (Fri, 16-Oct 9:38 AM)

Tempus unit Ambry launches GenomeNext, pairing whole genome sequencing with RNA analysis and ongoing reanalysis for rare-disease diagnosis

Market Chameleon (Tue, 13-Oct 8:42 AM)

Tempus Broadens Collaboration With Moderna and Merck to Build the Sample-to-Sequencing Workflow for V940

Market Chameleon (Wed, 7-Oct 8:37 AM)

Tempus wins FDA clearance for ECG-MR, its fourth ECG-AI tool targeting moderate-to-severe mitral regurgitation

Market Chameleon (Mon, 28-Sep 8:16 AM)

Tempus Extends Recursion Partnership Through 2029 and Adds License to TxFM RNA Foundation Model

Market Chameleon (Mon, 21-Sep 9:48 AM)

Tempus Gains FDA Clearance for Third AI Cardiovascular Device, Targeting Early Detection of Pulmonary Hypertension

Market Chameleon (Mon, 24-Aug 8:52 AM)

Tempus AI Raises 2026 Guidance and Returns to Profit—Sector Expectations Remain High

Market Chameleon (Mon, 10-Aug 9:21 AM)

Tempus Partnership Expands CellCarta’s Oncology Diagnostics Network—What This Means for CDx Commercialization

Market Chameleon (Thu, 6-Aug 9:47 AM)

PRISM2 Delivers Record-Setting Results in Cancer Diagnosis and Prognosis, Backed by 2.3 Million Pathology Images

Market Chameleon (Tue, 4-Aug 8:57 AM)